IMMUNE NETWORK

The Korean Association of Immunobiologists (대한면역학회)
권호 표지

Effect of Lipofectin on Antigen-presenting Function and Anti-tumor Activity of Dendritic Cells

수지상세포의 항원제시 능력 및 항암활성에 미치는 Lipofectin의 영향

  • Noh, Young-Woock (Department of Biological Sciences, Sookmyung Women's University) ;
  • Lim, Jong-Seok (Department of Biological Sciences, Sookmyung Women's University)
  • 노영욱 (숙명여자대학교 생명과학과) ;
  • 임종석 (숙명여자대학교 생명과학과)
  • Published : 2006.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Dendritic cells (DC) are professional antigen-presenting cells in the immune system and can induce T cell response against virus infections, microbial pathogens, and tumors. Therefore, immunization using DC loaded with tumor-associated antigens (TAAs) is a powerful method of inducing anti-tumor immunity. For induction of effective anti-tumor immunity, antigens should be efficiently introduced into DC and presented on MHC class I molecules at high levels to activate antigen-specific $CD8^+$ T cells. We have been exploring methods for loading exogenous antigens into APC with high efficiency of Ag presentation. In this study, we tested the effect of the cationic liposome (Lipofectin) for transferring and loading exogenous model antigen (OVA protein) into BM-DC. Methods: Bone marrow-derived DC (EM-DC) were incubated with OVA-Lipofectin complexes and then co-cultured with B3Z cells. B3Z activation, which is expressed as the amount of ${\beta}$-galactosidase induced by TCR stimulation, was determined by an enzymatic assay using ${\beta}$-gal assay system. C57BL/6 mice were immunized with OVA-pulsed DC to monitor the in vivo vaccination effect. After vaccination, mice were inoculated with EG7-OVA tumor cells. Results: BM-DC pulsed with OVA-Lipofectin complexes showed more efficient presentation of OVA-peptide on MHC class I molecules than soluble OVA-pulsed DC. OVA-Lipofectin complexes-pulsed DC pretreated with an inhibitor of MHC class I-mediated antigen presentation, brefeldin A, showed reduced ability in presenting OVA peptide on their surface MHC class I molecules. Finally, immunization of OVA-Lipofectin complexes-pulsed DC protected mice against subsequent tumor challenge. Conclusion: Our data provide evidence that antigen-loading into DC using Lipofectin can promote MHC class I- restricted antigen presentation. Therefore, antigen-loading into DC using Lipofectin can be one of several useful tools for achieving efficient induction of antigen-specific immunity in DC-based immunotherapy.

Keywords

References

  1. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 392;245-252, 1998 https://doi.org/10.1038/32588
  2. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K: Immunobiology of dendritic cells. Annu Rev Immunol 18;767-811, 2000 https://doi.org/10.1146/annurev.immunol.18.1.767
  3. Hilkens CM, Kalinski P, de Boer M, Kapsenberg ML: Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood 90;1920-1926, 1997
  4. Nouri-Shirazi M, Banchereau J, Fay J, Palucka K: Dendritic cell based tumor vaccines. Immunol Letter 74;5-10, 2000 https://doi.org/10.1016/S0165-2478(00)00243-1
  5. Whiteside TL, Odoux C: Dendritic cell biology and cancer therapy. Cancer Immunol Immunother 53;240-248, 2004 https://doi.org/10.1007/s00262-003-0468-6
  6. Milazzo C, Reichardt VL, Muller MR, Grunebach F, Brossart P: Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 101; 977-982, 2003 https://doi.org/10.1182/blood-2002-04-1273
  7. Schuler G, Schuler-Thurner B, Steinman RM: The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15; 138-147, 2003 https://doi.org/10.1016/S0952-7915(03)00015-3
  8. Kim A, Kim KD, Choi SC, Jeong MJ, Lee HG, Choe YK, Paik SG, Lim JS: IL-12 production and subsequent natural killer cell activation by necrotic tumor cell-loaded dendritic cells in therapeutic vaccinations. Immune Network 3;188-200, 2003 https://doi.org/10.4110/in.2003.3.3.188
  9. Moore MW, Carbone FR, Bevan MJ: Introduction of solubleprotein into the class-I pathway of antigen processing and presentation. Cell 54;777-785, 1988 https://doi.org/10.1016/S0092-8674(88)91043-4
  10. Karttunen J, Sanderson S, Shastri N: Detection of rare antigenpresenting cells by the LacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc Natl Acad Sci USA 89;6020-6024, 1992
  11. Shen Z, Renznikoff G, Dranoff G, Rock KL: Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 158;2723-2730, 1997
  12. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM: Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with mouse bone marrow cultures supplemented with granulocyte/ macrophage colony-stimulating factor. J Exp Med 176; 1693-1702, 1992 https://doi.org/10.1084/jem.176.6.1693
  13. Shastri N, Gonzalez F: Endogenous generation and presentation of the ovalbumin peptide/k(b) complex to T-cells. J Immunol 150;2724-2736, 1993
  14. Kim A, Noh YW, Kim KD, Jang YS, Choe YK, Lim JS: Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination. Exp Mol Med 36;428-443, 2004 https://doi.org/10.1038/emm.2004.55
  15. Porgador A, Snyder D, Gilboa E: Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 156;2918-2926, 1996
  16. De Veerman M, Heirman C, Van Meirvenne S, Devos S, Corthals J, Moser M, Thielemans K: Retrovirally transduced bone marrow-derived dendritic cells require $CD4^+$ T cell help to elicit protective and therapeutic antitumor immunity. J Immunol 162; 144-151, 1999
  17. Rosenberg SA: A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10;281-287, 1999 https://doi.org/10.1016/S1074-7613(00)80028-X
  18. Norbury CC, Chambers BJ, Prescott AR, Ljunggren HG, Watts C: Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur J Immunol 27;280-288, 1997
  19. Shen Z, Reznikoff G, Dranoff G, Rock KL: Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 158;2723-2730, 1997
  20. Sallusto F, Cella M, Danieli C, Lanzavecchia A: Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 182;389-400, 1995 https://doi.org/10.1084/jem.182.2.389
  21. Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S: Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1;362-368, 1999 https://doi.org/10.1038/14058
  22. Okada N, Tsujino M, Hagiwara Y, Tada A, Tamura Y, Mori K, Saito T, Nakagawa S, Mayumi T, Fujita T, Yamamoto A: Administration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens. Br J Cancer 84;1564-1570, 2001 https://doi.org/10.1054/bjoc.2001.1801
  23. Galea-Lauri J, Wells J, Darling D, Harrison P, Farzaneh F: Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Cancer Immunol Immunother 53;963-977, 2004
  24. Eriksson K, Sun JB, Nordstrom I, Fredriksson M, Lindblad M, Li BL, Holmgren J: Coupling of antigen to cholera toxin for dendritic cell vaccination promotes the induction of MHC class I-restricted cytotoxic T cells and the rejection of a cognate antigen-expressing model tumor. Eur J Immunol 34;1272-1281, 2004 https://doi.org/10.1002/eji.200324368
  25. Kim KW, Kim SH, Jang JH, Lee EY, Park SW, Um JH, Lee YJ, Lee CH, Yoon S, Seo SY, Jeong MH, Lee ST, Chung BS, Kang CD: Dendritic cells loaded with exogenous antigen by electroporation can enhance MHC class I-mediated antitumor immunity. Cancer Immunol Immunother 53;315-522, 2004 https://doi.org/10.1007/s00262-003-0448-x
  26. Bungener L, Serre K, Bijl L, Leserman L, Wilschut J, Daemen T, Machy P. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 20;2287-2295, 2002 https://doi.org/10.1016/S0264-410X(02)00103-2
  27. Nakanishi T, Hayashi A, Kunisawa J, Tsutsumi Y, Tanaka K, Yashiro-Ohtani Y, Nakanishi M, Fujiwara H, Hamaoka T, Mayumi T: Fusogenic liposomes efficiently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway. Eur J Immunol 30;1740-1747, 2000 https://doi.org/10.1002/1521-4141(200006)30:6<1740::AID-IMMU1740>3.0.CO;2-U